metformin has been researched along with Coronary Disease in 67 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 9.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "In 20 adolescents age < or = 17 (16 +/- 1 yr) with polycystic ovary syndrome (PCOS), we assessed efficacy and safety of metformin-diet for 1 year in treatment of endocrinopathy and coronary heart disease (CHD) risk factors." | 9.14 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Wang, P, 2009) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 9.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 9.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| "Metformin lowered the LDL/HDL-cholesterol ratio by 12 and 6% at weeks 4 and 12, respectively, and reduced body weight by 1." | 9.08 | Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. ( Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O, 1996) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "The literature dealing with diabetes mellitus, B vitamins and metformin was reviewed." | 8.81 | Homocysteine and cardiovascular risk in patients with diabetes mellitus. ( Lavie, L; Levy, Y; Yeromenko, Y, 2001) |
| "Aim of the study was to clarify the relationship between metformin-induced vitamin B12 (B12) deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes." | 7.79 | Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. ( Aizawa, T; Funase, Y; Ouchi, K; Sato, Y; Yamauchi, K, 2013) |
| "To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism." | 7.78 | [Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism]. ( Kaĭdashev, IP; Kutsenko, LA; Lavrenko, AV; Mamontova, TV; Shlykova, OA, 2012) |
| "To evaluate whether the risk of coronary heart disease (CHD) differs among adult diabetic patients treated with thiazolidinediones (TZDs) and similar patients treated with combined oral metformin and sulfonylurea (M + S) therapy." | 7.74 | The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. ( Cutone, JA; Johannes, CB; Koro, CE; Quinn, SG; Seeger, JD, 2007) |
| "55 g/d for 28 weeks) would ameliorate morbid obesity and reduce centripetal obesity; lipid and lipoprotein cholesterol, insulin, and leptin levels; and plasminogen activator inhibitor activity (PAI-Fx), risk factors for coronary heart disease (CHD)." | 7.71 | Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. ( Fontaine, RN; Glueck, CJ; Illig, E; Lang, JE; McCullough, P; Sieve-Smith, L; Streicher, P; Subbiah, MT; Tracy, TM; Wang, P; Weber, K, 2001) |
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 5.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "Metformin was associated with a reduced risk of CHF (HR 0." | 5.35 | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. ( Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS, 2009) |
| "We sought to determine whether insulin-sensitizing therapy (thiazolidinediones or metformin) decreased the risk of developing atrial fibrillation compared with insulin-providing therapy (insulin, sulfonylurea, or a meglitinide)." | 5.27 | Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease. ( Boothroyd, DB; Brooks, MM; Chaitman, BR; Hlatky, MA; Pallisgaard, JL; Perez, M, 2018) |
| "In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months." | 5.22 | Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. ( Ala-Korpela, M; Holman, RR; Kangas, AJ; Preiss, D; Rankin, N; Sattar, N; Soininen, P; Welsh, P; Würtz, P, 2016) |
| "In 20 adolescents age < or = 17 (16 +/- 1 yr) with polycystic ovary syndrome (PCOS), we assessed efficacy and safety of metformin-diet for 1 year in treatment of endocrinopathy and coronary heart disease (CHD) risk factors." | 5.14 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Wang, P, 2009) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 5.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "Metformin lowered the LDL/HDL-cholesterol ratio by 12 and 6% at weeks 4 and 12, respectively, and reduced body weight by 1." | 5.08 | Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. ( Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O, 1996) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 5.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "To evaluate the role of laparoscopic ovarian drilling and treatment with metformin in the management of the polycystic ovary syndrome (PCOS)." | 4.82 | Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? ( Pirwany, I; Tulandi, T, 2003) |
| "The literature dealing with diabetes mellitus, B vitamins and metformin was reviewed." | 4.81 | Homocysteine and cardiovascular risk in patients with diabetes mellitus. ( Lavie, L; Levy, Y; Yeromenko, Y, 2001) |
| " On the other hand, treatment of obese patients with metformin significantly reduced the incidence of myocardial infarction and of mortality diabetes related." | 4.80 | [Should the occurrence of a first coronary event change the management of diabetes?]. ( Dubois-Laforgue, D; Timsit, J, 2000) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "Aim of the study was to clarify the relationship between metformin-induced vitamin B12 (B12) deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes." | 3.79 | Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. ( Aizawa, T; Funase, Y; Ouchi, K; Sato, Y; Yamauchi, K, 2013) |
| "To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism." | 3.78 | [Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism]. ( Kaĭdashev, IP; Kutsenko, LA; Lavrenko, AV; Mamontova, TV; Shlykova, OA, 2012) |
| "To evaluate whether the risk of coronary heart disease (CHD) differs among adult diabetic patients treated with thiazolidinediones (TZDs) and similar patients treated with combined oral metformin and sulfonylurea (M + S) therapy." | 3.74 | The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. ( Cutone, JA; Johannes, CB; Koro, CE; Quinn, SG; Seeger, JD, 2007) |
| "To assess the risk of myocardial infarction (MI) and coronary revascularization (CR), in diabetic patients who began rosiglitazone, pioglitazone, metformin, or sulfonylureas." | 3.74 | Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. ( Koro, CE; Landon, J; Walker, AM, 2008) |
| "55 g/d for 28 weeks) would ameliorate morbid obesity and reduce centripetal obesity; lipid and lipoprotein cholesterol, insulin, and leptin levels; and plasminogen activator inhibitor activity (PAI-Fx), risk factors for coronary heart disease (CHD)." | 3.71 | Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. ( Fontaine, RN; Glueck, CJ; Illig, E; Lang, JE; McCullough, P; Sieve-Smith, L; Streicher, P; Subbiah, MT; Tracy, TM; Wang, P; Weber, K, 2001) |
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | 2.76 | Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| "Treatment with metformin reduced mortality due to cardiovascular disease in obese patients." | 2.40 | [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications]. ( Heine, RJ; Wolffenbuttel, BH, 1999) |
| "Both hyperinsulinemia and hyperglycemia have been suggested as risk factors for accelerated atherogenesis in diabetes." | 2.39 | Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease? ( Giugliano, D, 1996) |
| "Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion." | 1.43 | Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. ( Ekström, N; Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Miftaraj, M; Svensson, AM; Zethelius, B, 2016) |
| "Metformin was associated with a reduced risk of CHF (HR 0." | 1.35 | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. ( Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS, 2009) |
| "Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0." | 1.34 | Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. ( Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH, 2007) |
| "Treatment with metformin led to decreased diabetes-induced TxCAD in the larger vessels." | 1.31 | Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin. ( Cantin, B; Dai, X; Gwathmey, JK; Panchal, SN; Reaven, GM; Valantine, HA; Wen, P; Zhu, D, 2002) |
| "Sixteen patients with NIDDM who had demonstrated a fall in fasting plasma glucose concentration > 2." | 1.29 | Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. ( Chen, YD; Jeppesen, J; Reaven, GM; Zhou, MY, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (14.93) | 18.7374 |
| 1990's | 14 (20.90) | 18.2507 |
| 2000's | 26 (38.81) | 29.6817 |
| 2010's | 14 (20.90) | 24.3611 |
| 2020's | 3 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, W | 1 |
| Zhou, Y | 1 |
| Sun, L | 1 |
| Liu, J | 1 |
| Cheng, Z | 1 |
| Zhao, S | 1 |
| Gebreyesus, HA | 1 |
| Abreha, GF | 1 |
| Besherae, SD | 1 |
| Abera, MA | 1 |
| Weldegerima, AH | 1 |
| Gidey, AH | 1 |
| Bezabih, AM | 1 |
| Lemma, TB | 1 |
| Nigatu, TG | 1 |
| Gao, B | 1 |
| Gao, W | 1 |
| Wan, H | 1 |
| Xu, F | 1 |
| Zhou, R | 1 |
| Zhang, X | 1 |
| Ji, Q | 1 |
| Pallisgaard, JL | 1 |
| Brooks, MM | 3 |
| Chaitman, BR | 2 |
| Boothroyd, DB | 1 |
| Perez, M | 1 |
| Hlatky, MA | 2 |
| Hung, YC | 1 |
| Lin, CC | 1 |
| Wang, TY | 1 |
| Chang, MP | 1 |
| Sung, FC | 1 |
| Chen, CC | 1 |
| Sato, Y | 1 |
| Ouchi, K | 1 |
| Funase, Y | 1 |
| Yamauchi, K | 1 |
| Aizawa, T | 1 |
| Lexis, CP | 1 |
| van der Horst, IC | 1 |
| Riksen, NP | 1 |
| el Messaoudi, S | 1 |
| Rongen, GA | 1 |
| Preiss, D | 2 |
| Lloyd, SM | 1 |
| Ford, I | 1 |
| McMurray, JJ | 1 |
| Holman, RR | 2 |
| Welsh, P | 2 |
| Fisher, M | 1 |
| Packard, CJ | 1 |
| Sattar, N | 2 |
| Fath, R | 1 |
| Fung, CS | 1 |
| Wan, EY | 1 |
| Wong, CK | 1 |
| Jiao, F | 1 |
| Chan, AK | 1 |
| Rankin, N | 1 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Würtz, P | 1 |
| Ala-Korpela, M | 1 |
| Ekström, N | 1 |
| Svensson, AM | 1 |
| Miftaraj, M | 1 |
| Franzén, S | 1 |
| Zethelius, B | 1 |
| Eliasson, B | 1 |
| Gudbjörnsdottir, S | 1 |
| O'Connor, PJ | 1 |
| Sperl-Hillen, JM | 1 |
| Johnson, PE | 1 |
| Rush, WA | 1 |
| Asche, SE | 1 |
| Dutta, P | 1 |
| Biltz, GR | 1 |
| Pantalone, KM | 1 |
| Kattan, MW | 1 |
| Yu, C | 1 |
| Wells, BJ | 1 |
| Arrigain, S | 1 |
| Jain, A | 1 |
| Atreja, A | 1 |
| Zimmerman, RS | 1 |
| Frye, RL | 2 |
| August, P | 1 |
| Hardison, RM | 2 |
| Kelsey, SF | 1 |
| MacGregor, JM | 1 |
| Orchard, TJ | 1 |
| Genuth, SM | 1 |
| Goldberg, SH | 1 |
| Jones, TL | 1 |
| Molitch, ME | 1 |
| Nesto, RW | 1 |
| Sako, EY | 1 |
| Sobel, BE | 2 |
| Glueck, CJ | 3 |
| Goldenberg, N | 1 |
| Wang, P | 3 |
| Störk, S | 1 |
| Ertl, G | 1 |
| Nitschmann, S | 1 |
| Genuth, S | 1 |
| McBane, RD | 1 |
| Schneider, DJ | 1 |
| Pratley, RE | 1 |
| Huber, K | 1 |
| Wolk, R | 1 |
| Krishnaswami, A | 1 |
| Lavrenko, AV | 1 |
| Shlykova, OA | 1 |
| Kutsenko, LA | 1 |
| Mamontova, TV | 1 |
| Kaĭdashev, IP | 1 |
| Tuomilehto, J | 1 |
| Pirwany, I | 1 |
| Tulandi, T | 1 |
| CHAKRABARTI, R | 3 |
| HOCKING, ED | 2 |
| FEARNLEY, GR | 5 |
| Després, JP | 1 |
| Schäfers, RF | 1 |
| Zimmer, P | 1 |
| von Bibra, H | 1 |
| Hansen, A | 1 |
| Dounis, V | 1 |
| Bystedt, T | 1 |
| Malmberg, K | 1 |
| Rydén, L | 1 |
| Nauck, MA | 1 |
| Matthaei, S | 1 |
| Lynch, T | 1 |
| Aregawi, D | 1 |
| Winiarska, M | 1 |
| Agloria, M | 1 |
| Luo, G | 1 |
| Sieve, L | 1 |
| Schindler, TH | 1 |
| Facta, AD | 1 |
| Prior, JO | 1 |
| Cadenas, J | 1 |
| Hsueh, WA | 1 |
| Quinones, MJ | 1 |
| Schelbert, HR | 1 |
| Johannes, CB | 1 |
| Koro, CE | 2 |
| Quinn, SG | 1 |
| Cutone, JA | 1 |
| Seeger, JD | 1 |
| Kraemer de Aguiar, LG | 1 |
| Laflor, CM | 1 |
| Bahia, L | 1 |
| Villela, NR | 1 |
| Wiernsperger, N | 1 |
| Bottino, DA | 1 |
| Bouskela, E | 1 |
| Chang, Y | 1 |
| Choi, NK | 1 |
| Hahn, S | 1 |
| Park, BJ | 1 |
| Fisman, EZ | 2 |
| Motro, M | 2 |
| Tenenbaum, A | 1 |
| Walker, AM | 1 |
| Landon, J | 1 |
| Sirtori, CR | 1 |
| Tremoli, E | 1 |
| Paoletti, R | 1 |
| Sgambato, S | 1 |
| Varricchio, M | 2 |
| Tesauro, P | 1 |
| Passariello, N | 1 |
| Carbone, L | 1 |
| Bloomgarden, ZT | 1 |
| Schneider, J | 1 |
| Jeppesen, J | 1 |
| Zhou, MY | 1 |
| Chen, YD | 1 |
| Reaven, GM | 2 |
| Hoogeveen, EK | 1 |
| Stehouwer, CD | 1 |
| Carlsen, SM | 4 |
| Rossvoll, O | 1 |
| Bjerve, KS | 2 |
| Følling, I | 4 |
| Giugliano, D | 1 |
| Katayama, S | 1 |
| Grill, V | 3 |
| Schneede, J | 1 |
| Refsum, H | 1 |
| Waage, A | 1 |
| Wolffenbuttel, BH | 1 |
| Heine, RJ | 1 |
| Holstein, A | 1 |
| Nahrwold, D | 1 |
| Hinze, S | 1 |
| Egberts, EH | 1 |
| Haffner, SM | 1 |
| Timsit, J | 1 |
| Dubois-Laforgue, D | 1 |
| Yeromenko, Y | 1 |
| Lavie, L | 1 |
| Levy, Y | 1 |
| Fontaine, RN | 1 |
| Subbiah, MT | 1 |
| Weber, K | 1 |
| Illig, E | 1 |
| Streicher, P | 1 |
| Sieve-Smith, L | 1 |
| Tracy, TM | 1 |
| Lang, JE | 1 |
| McCullough, P | 1 |
| Tenenbaum , A | 1 |
| Boyko, V | 1 |
| Benderly, M | 1 |
| Adler, Y | 1 |
| Friedensohn, A | 1 |
| Kohanovski, M | 1 |
| Rotzak, R | 1 |
| Schneider, H | 1 |
| Behar, S | 1 |
| Cantin, B | 1 |
| Zhu, D | 1 |
| Wen, P | 1 |
| Panchal, SN | 1 |
| Dai, X | 1 |
| Gwathmey, JK | 1 |
| Valantine, HA | 1 |
| Verstraete, M | 1 |
| Cacciapuoti, F | 1 |
| Spiezia, R | 1 |
| Bianchi, U | 1 |
| Lama, D | 1 |
| D'Avino, M | 1 |
| Isnard, F | 1 |
| André, P | 1 |
| Evans, JF | 1 |
| Gormsen, J | 1 |
| Evans, J | 1 |
| Molino, N | 1 |
| Belluardo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study[NCT03794336] | Phase 4 | 1,293 participants (Actual) | Interventional | 2019-06-29 | Completed | ||
| Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial[NCT02318446] | Phase 3 | 36 participants (Anticipated) | Interventional | 2015-03-31 | Not yet recruiting | ||
| The Metformin in CABG (MetCAB) Trial[NCT01438723] | Phase 4 | 100 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomised Placebo-controlled Trial of Metformin on Progression of Carotid Atherosclerosis in Non-diabetic Patients With Cardiovascular Disease Treated With Conventional Risk Reducing Agents[NCT00723307] | Phase 4 | 173 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| SimCare: Physician Intervention to Improve Diabetes Care[NCT00262704] | 2,020 participants (Actual) | Interventional | 2001-12-31 | Completed | |||
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes.[NCT00747409] | Phase 4 | 120 participants (Anticipated) | Interventional | 2004-07-31 | Active, not recruiting | ||
| Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study[NCT01004757] | 41 participants (Anticipated) | Interventional | 2008-02-29 | Active, not recruiting | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
14 reviews available for metformin and Coronary Disease
| Article | Year |
|---|---|
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure?
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Gynecologic Surgical Procedures; Humans; Hypogl | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
Do effects on blood pressure contribute to improved clinical outcomes with metformin?
Topics: Blood Pressure; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type | 2003 |
[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].
Topics: Acarbose; Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2005 |
Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
Topics: Benzamides; Biguanides; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Humans; | 2008 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterifie | 1980 |
Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease?
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; Hyperinsulinism; Hypogl | 1996 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1999 |
[Should the occurrence of a first coronary event change the management of diabetes?].
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Antagonists; Blood Glucose; Cardiovascular Agents; | 2000 |
Homocysteine and cardiovascular risk in patients with diabetes mellitus.
Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus; Homocysteine; Humans; Hyperhomocysteine | 2001 |
The position of long-term stimulation of the endogenous fibrinolytic system: present achievements and clinical perspectives.
Topics: Adrenocorticotropic Hormone; Anabolic Agents; Androgens; Clofibrate; Coronary Disease; Deamino Argin | 1975 |
[Identification and prevention of vascular risk. Significance of metformin].
Topics: Anthropometry; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; I | 1990 |
15 trials available for metformin and Coronary Disease
| Article | Year |
|---|---|
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi
Topics: Acarbose; Adult; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated | 2022 |
Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.
Topics: Atrial Fibrillation; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent | 2018 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study.
Topics: Adult; Amino Acids; Amino Acids, Branched-Chain; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2016 |
Simulated physician learning intervention to improve safety and quality of diabetes care: a randomized trial.
Topics: Adult; Aged; Cholesterol, LDL; Computer Simulation; Coronary Disease; Diabetes Mellitus; Diabetes Me | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2009 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Combined Modality Therapy; Coronary Disease; Diet, Reducing; Female; Humans; Hypoglycemi | 2009 |
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Adult; Biomarkers; C-Reactive Protein; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2011 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Cholesterol; Coronary Disease; Diet; Female; Humans; Insulin; Insulin Resistance; | 2006 |
Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
Topics: Adult; Capillaries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind | 2007 |
Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Coronary Disease; Diet; Humans; Hyperlipidemi | 1996 |
Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.
Topics: Adult; Coronary Disease; Cysteine; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Male; Metf | 1997 |
Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.
Topics: Adult; Blood Glucose; Coronary Disease; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin | 1998 |
Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus.
Topics: Adult; Angina Pectoris; Blood Glucose; Cardiac Complexes, Premature; Coronary Disease; Diabetes Mell | 1991 |
38 other studies available for metformin and Coronary Disease
| Article | Year |
|---|---|
Potential Effects of Metformin on the Vitality, Invasion, and Migration of Human Vascular Smooth Muscle Cells via Downregulating lncRNA-ATB.
Topics: Coronary Disease; Down-Regulation; Genes, p53; Humans; Metformin; Muscle, Smooth, Vascular; RNA, Lon | 2022 |
High atherogenic risk concomitant with elevated HbA1c among persons with type 2 diabetes mellitus in North Ethiopia.
Topics: Adult; Aged; Comorbidity; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Ethi | 2022 |
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Di | 2013 |
Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes.
Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Diet | 2013 |
Metformin for cardiovascular disease: promise still unproven.
Topics: Carotid Intima-Media Thickness; Coronary Disease; Female; Humans; Hypoglycemic Agents; Male; Metabol | 2014 |
It takes more than one CAMERA to study cardiovascular protection by metformin.
Topics: Carotid Intima-Media Thickness; Coronary Disease; Female; Humans; Hypoglycemic Agents; Male; Metform | 2014 |
[Effective prevention of coronary heart disease by early diabetes therapy].
Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early M | 2015 |
Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.
Topics: Aged; Asian People; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Ty | 2015 |
Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Topics: Aged; Blood Glucose; Cardiotoxicity; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, T | 2016 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitu | 2009 |
[Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].
Topics: Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Byp | 2010 |
Metabolic syndrome and mental illness. Weight gain and other unhealthy attributes increase risk of diabetes and heart disease.
Topics: Antipsychotic Agents; Blood Glucose; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, | 2011 |
[Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism].
Topics: Aged; Alleles; Body Weight; Case-Control Studies; Coronary Disease; Cytokines; Diabetes Mellitus, Ty | 2012 |
[Blood glucose control with high dosage metformin. So that sweet hearts beat longer].
Topics: Blood Glucose; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response | 2002 |
FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE.
Topics: Arteries; Biomedical Research; Blood Coagulation Tests; Cholesterol; Coronary Artery Disease; Corona | 1965 |
[Physical activity in hyperglycemia and type 2 diabetes. Effective but still underutilized].
Topics: Adult; Aged; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Exercise; Female | 2003 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and C | 2006 |
Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Case-Control Studies; Coronary Circulation; Coronary Disease; Diabete | 2007 |
The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cohort Studies; Coronary Disease; Databases, Factual; | 2007 |
A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2007 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2008 |
[The use of metformin in ischemic cardiopathy].
Topics: Adult; Coronary Disease; Diabetic Angiopathies; Female; Humans; Male; Metformin; Middle Aged | 1980 |
Metformin.
Topics: Blood Glucose; Controlled Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Dia | 1995 |
[Metformin in patients with coronary disease?].
Topics: Acidosis, Lactic; Contraindications; Coronary Disease; Humans; Lactates; Lactic Acid; Metformin; Ris | 1995 |
Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, | 1994 |
Should metformin be used to improve blood lipid pattern in nondiabetic patients with coronary heart disease?
Topics: Coronary Disease; Homocysteine; Humans; Hypoglycemic Agents; Lipids; Metformin; Risk Factors | 1996 |
Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease.
Topics: Adult; Coronary Disease; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obe | 1998 |
Contra-indications to metformin therapy are largely disregarded.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coronary Disease; Cross-Sectional Studies; Diabet | 1999 |
Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Clinical Trials as Topic; Corona | 2001 |
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Topics: Adult; Aged; Body Mass Index; Body Weight; Cholesterol, LDL; Coronary Disease; Fasting; Female; Huma | 2001 |
Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glybur | 2001 |
Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Coronary Disease; Diabetes Mellitus, Experimental; | 2002 |
Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease.
Topics: Aged; Anticholesteremic Agents; Blood Coagulation Tests; Blood Platelets; Butyrates; Cholesterol; Co | 1968 |
Fibrinolytic activity and haemagglutination inhibition immunoassays.
Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi | 1970 |
[Physiological and pharmacological aspects of fibrinolysis].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Arteriosclerosis Obliterans; Biguanides; Blood Coagulation | 1971 |
Fibrinolytic effect of biguanides.
Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis Obliterans; Biguanides; Chlorpropamide; Coronary Dise | 1968 |
[Comparative study of the fibrinolytic activity of dimethylbiguanide in prevention of thromboembolism in patients with angiocardiopathy].
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Dyspnea, Paroxysmal; Female; Humans; Hypertension; | 1968 |
Pharmacological fibrinolysis.
Topics: Aged; Androsterone; Anticholesteremic Agents; Butyrates; Chlorpropamide; Coronary Disease; Ethylestr | 1969 |